Galapagos has announced that its service division, BioFocus DPI, has initiated a drug discovery collaboration with Schering-Plough Research Institute (SPRI).
As per the agreement, BioFocus DPI would perform medicinal chemistry with supporting biology and ADME/PK services for multiple Schering-Plough drug discovery projects. Total contract value for Galapagos is E2.8m over a one year period.
Building on a collaboration established in May 2009 and expanded this month, BioFocus DPI scientists would work with two of SPRI’s European sites on these drug discovery projects, said the company.
Onno van de Stolpe, CEO of Galapagos, said: “We are pleased to build on our collaborative relationship with SPRI, which has evolved into one of the larger for BioFocus DPI this year with over 20 research staff currently engaged. BioFocus DPI has proven resilient in securing large collaborations with strong partners, amidst consolidation and reorganisation in the pharma industry.”
Galapagos is a drug discovery and development company with small molecule programs in bone and joint diseases, bone metastasis, cachexia, anti-infectives and metabolic diseases.
BioFocus DPI provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as ADMET products to select compounds.